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Abstract
In mammals DNA methylation occurs at position 5 of cytosine in a CpG context and regulates gene expression. It plays an
important role in diseases and inhibitors of DNA methyltransferases (DNMTs)—the enzymes responsible for DNA
methylation—are used in clinics for cancer therapy. The most potent inhibitors are 5-azacytidine and 5-azadeoxycytidine.
Zebularine (1-(b-D-ribofuranosyl)-2(1H)- pyrimidinone) is another cytidine analog described as a potent inhibitor that acts
by forming a covalent complex with DNMT when incorporated into DNA. Here we bring additional experiments to explain
its mechanism of action. First, we observe an increase in the DNA binding when zebularine is incorporated into the DNA,
compared to deoxycytidine and 5-fluorodeoxycytidine, together with a strong decrease in the dissociation rate. Second, we
show by denaturing gel analysis that the intermediate covalent complex between the enzyme and the DNA is reversible,
differing thus from 5-fluorodeoxycytidine. Third, no methylation reaction occurs when zebularine is present in the DNA. We
confirm that zebularine exerts its demethylation activity by stabilizing the binding of DNMTs to DNA, hindering the
methylation and decreasing the dissociation, thereby trapping the enzyme and preventing turnover even at other sites.
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Introduction
Cancer cells show a highly disturbed epigenetic landscape,
which often features a global hypomethylation of the genome that
induces abnormal expression of genes and a local hypermethyla-
tion of promotors that silences tumor suppressor genes (TSG)
[1,2]. DNA methylation is catalyzed by a family of enzymes called
DNA methyltransferases (DNMTs) and occurs in mammals only
at position 5 of cytosines in CpG dinucleotides [3]. All DNMTs
use S-adenosyl-L-methionine (AdoMet) as methyl group donor. A
key feature of the catalytic mechanism of DNMTs is a nucleophilic
attack of the enzyme on the carbon-6 of the target cytosine. This
attack is performed by the thiol group of the cysteine residue of a
conserved Proline-Cysteine-Glutamine (PCQ) motif in the active
site of DNMTs and is coupled with protonation of N3 to yield an
activated enamine intermediate [4,5]. This electron flow back into
the pyrimidine ring leads to activation of the C5 atom towards
electrophilic attack and thus to the addition of the methyl group
from the cofactor AdoMet to the cytosine. This step is followed by
elimination of the C5 proton and resolution of the covalent
intermediate. DNMTs are responsible for de novo DNA methyla-
tion as well as maintenance of methylation. In eukaryotes different
DNMT families are described; DNMT1 is known as the
maintenance methyltransferase, since it preferentially binds and
methylates hemimethylated DNA; whereas DNMT3a and 3b act
as de novo methyltransferases. DNMT3L, required for the
establishment of maternal genomic imprints, lacks the catalytic
activity and participates in de novo methylation through stimulation
of DNMT3a [6].
Inactivation of DNMTs is the most effective way of inhibiting
DNA methylation and, thereby, removing the hypermethylation of
TSG promoters in cancer cells [7]. Therefore, many DNA
methylation inhibitors have been developed. Among them, 5-
azacytidine (5-aza-CR, VidazaH) and 5-azadeoxycytidine (5-aza-
CdR, DacogenH) (Fig. 1) have gained FDA approval for the
treatment of myelodysplastic syndrome, a preleukemic bone
marrow disorder [8,9]. These compounds are cytidine analogues
that once incorporated into the DNA covalently trap the DNMTs
on the DNA by forming a suicide complex. After DNMT binding
to the C6 of the 5-aza-CdR incorporated into the DNA, methyl
group transfer will occur, but no H is present on the N5, which
precludes the resolution of the complex [10,11]. As a result of the
irreversibility of the covalent complex, further methylation of
cytosine residues is inhibited [12,13], leading to a massive loss of
DNA methylation [14]. The resulting hypomethylation of the
genome has been associated with the activation of certain genes
previously silenced [15,16] and among them TSG [17].
One disadvantage of the azanucleosides is their instability in
aqueous solutions [18,19], but this can be overcomed by the use of
other more stable analogues, such as zebularine or 5 fluoro-
deoxycytidine (5-F-CdR) (Fig. 1A), which also inhibit DNA
methylation after incorporation into DNA [17]. 5-F-CdR has
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12388Figure 1. Structure of the inhibitors and sequence of the duplexes used in this study. (A) Nucleosides used to trap cytosine-5
methyltransferases (DNMTs) in comparison to deoxycytidine. (B) Sequences of the oligonucleotides: CdR indicates deoxycytidine, Z indicates
zebularine, 5-F-CdR indicates 5-fluorodeoxycytidine, M indicates 5-methyldeoxycytidine, ss single-stranded DNA, ds double-stranded DNA, mds
hemimethylated DNA duplex. The CpG site are underlined.
doi:10.1371/journal.pone.0012388.g001
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once incorporated in DNA traps covalently the DNMT [21]. After
C6 attack and transfer of the methyl group, no b-elimination can
occur with release of the enzyme, because of the presence of the
fluoro on C5 [22].
Zebularine [1-(b-D-ribofuranosyl)-2(1H)-pyrimidinone], a cyti-
dine lacking the 4-amino group, is the most recent addition to the
list of demethylating agents in the family of nucleoside analogues
(Fig. 1). It was first synthesized in 1961 and characterized as a
potent inhibitor of cytidine deaminase with antitumor properties
[23–25]. It was then described as a DNMT inhibitor [26–29],
inhibiting DNA methylation [30] and reactivating silenced genes
[31–33] similarly to 5-aza-CdR. Moreover, zebularine enhances
tumor cell chemo- and radiosensitivity [34] and has antimitogenic
and angiostatic activities [35,36]. Additionally, zebularine is very
stable and has a half-life of ca. 44 h at 37uC at pH 1.0 and ca.
508 h at pH 7.0, making oral administration of the drug possible.
Zebularine is also minimally cytotoxic in vitro and in vivo [31]. Its
low toxicity allowed it to be given continuously at low dose to
maintain demethylation for a prolonged period [37]. When 5-aza-
CR and 5-aza-CdR treatments are arrested, DNA is remethylated.
However, when cancer cells are transiently treated with 5-aza-
CdR and then subjected to a continuous treatment with
zebularine, remethylation is hindered and gene expression is
maintained, suggesting that a combinatorial treatment method
gives a better response in the inhibition of DNA methylation
[37–39]. However, zebularine is not without drawbacks and
further study is necessary to fully understand the clinical effects it
will have on cancer patients. For example, higher concentrations
of zebularine are needed to obtain similar levels of demethylation
in cells in comparison with 5-aza-CdR [40,41]. Moreover
zebularine suppresses the apoptotic potential of 5-fluorouracil
against human oral squamous cell carcinoma cells, indicating that
combination therapies have to be carefully investigated [42]. It has
also been shown that zebularine is a potent mutagen in Escherichia
coli [43].
Because of its potential, we were interested in elucidating the
mechanism of action of the drug. Recently, van Bemmel et al. [44]
have compared the interaction of zebularine-containing DNA with
bacterial M.Hha I and mammalian DNMT1 to 5-aza-CR-
containing DNA. They observe similar inhibition rates while the
ternary complex differs: 5-aza-CR forms an irreversible complex,
zebularine instead forms a reversible covalent complex. Accord-
ingly, this difference may account for the differing cytotoxicity
observed between the two inhibitors. Here, we further characterize
the complex formed by zebularine with bacterial and mammalian
DNMTs and propose a hypothesis for the increased stability of the
reversible covalent complex. In this study, we have chosen to use
5-F-CdR as comparison instead of the 5-aza derivatives for two
reasons. First, 5-F-CdR was shown, as 5-aza-CdR or 5-aza-CR, to
trap covalently the DNMTs once incorporated in the DNA [21].
Second, this nucleoside is stable and commercially available,
whereas 5-aza-CdR is instable in aqueous solution and cannot be
obtained commercially incorporated into DNA. First, the DNA
binding affinity of the tested DNMTs is increased when zebularine
is incorporated in the DNA duplex compared to cytidine and 5-
fluorodeoxycytidine. Second we detect no methylation on
zebularine. The absence of the 4-amino group seems to prevent
the activation of the cytosine C5 position and thus the methyl
group transfer. Third we fail to observe an irreversible covalent
complex by SDS-PAGE gel, in agreement with the observation of
van Bemmel et al. [44]. Fourth we show that the ternary complex
with AdoMet, DNMT and DNA containing zebularine is much
more stable than the one formed with unmodified DNA. The lack
of zebularine methylation can explain this stabilization as it has
been described that the steric clash due to the methylation of
position 5 of the base induces the dissociation of the DNA/enzyme
complex [45].
Results
Zebularine increases the DNA binding of DNMTs
We first analyze the capacity of zebularine-containing DNA (ds-
Z, Fig. 1B) to bind to the bacterial DNA methylase M.SssI. M.SssI
is used as a model system since it is the only known prokaryotic
DNMTs, which recognizes the short sequence CG, and thus has
the same specificity as mammalian DNMTs. In addition, it
contains all ten conserved motifs of C5-DNMTs [46]. Duplexes
ds-Z (containing zebularine) is compared to duplexes ds-C
(containing cytidine) and ds-F (containing 5-F-CdR).
The duplexes are incubated with M.SssI (10 and 25 fold excess)
in the buffer supplied by NEB, supplemented with 300 mMo f
AdoMet and 100 mg/mL of BSA. Incubations are carried out for
16 h at 16uC as Shigdel and He demonstrated by a time-course
experiment that it takes 16 h at 16uC to obtain efficient
irreversible cross-linking between a probe containing 5-F-CdR
and the bacterial methyltransferase M.HhaI [47]. We confirm that
the cross-linking efficacy between M.SssI and duplexe ds-F is
higher at 16uC than at 37uC. Half of the reaction mixtures was
loaded onto a 4% native TBE polyacrylamide gel (Fig. 2A), and
the other half on a 10% denaturing SDS-PAGE after boiling in
Laemmli buffer (Fig. 2B). In the native TBE gel (Fig. 2A), we can
see that M.SssI efficiently binds modified (ds-Z and ds-F) and non
modified (ds-C) duplexes as shown by the retarded band. To
determine the C50, concentration at which 50% of complex is
formed, we measured M.SssI binding on the three duplexes using
7 dose levels of M.SssI from 11 nM to 230 nM (Fig. S1). We find a
C50 of 6064 nM for ds-C (mean of two experiments), 4667n M
for ds-Z (mean of four experiments) and 6361 nM for ds-F (mean
of two experiments). This result clearly shows that zebularine
increases the affinity of the enzyme for the duplex and it is more
efficient than 5-fluorodeoxycytidine.
Zebularine failed to form an irreversible covalent
complex with DNMT
The loading of the samples on a denaturing 10% SDS gel after
boiling allows to determine the nature of the covalent complex
formed between zebularine-containing DNA and M.SssI. As
expected, the negative control ds-C did not show any cross-linking
(Fig. 2B, lanes 2 and 3). Interestingly, we fail to observe the
formation of a covalent complex between M.SssI and ds-Z (Fig. 2B,
lanes 5 and 6). This result is in agreement with the observations
reported by van Bemmel et al. [44]. They observed by SDS-PAGE
gel analysis that the ternary complex between a ds-DNA
containing zebularine and M.HhaI is reversible and heat labile.
As a positive control, we use ds-F that cross-links efficiently to
M.SssI, as shown by the appearance of two bands with retarded
mobility on the SDS-PAGE gel (Fig. 2B, lanes 8 and 9). The upper
band has a mobility of approximately 68 kDa corresponding to
M.SssI (42 kDa) bound to the duplex (26 kDa). The lower band
has a mobility of approximately 55 kDa, matching the molecular
weight of the single-stranded oligonucleotide (13 kDa) bound to
M.SssI. As control, the unmodified complementary strand of ds-F
duplex was radiolabeled (ds-F
# duplex) (Fig. 2B lane 10); and as
expected, only the band with the lowest mobility was detected,
corresponding to the enzyme covalently bound to the double-
stranded DNA and suggesting that the enzyme binds to the
modified strand. To confirm that the cross-link takes place on the
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loaded onto a denaturing sequencing polyacrylamide gel (Fig. S2).
M.SssI was covalently bound only to the radiolabeled strand
containing 5-F-CdR and after proteinase K treatment the
degradation products of the protein attached to this strand
appeared.
Next we analyze the nature of the binding between zebularine
or 5-F-CdR and the mammalian DNMTs: human DNMT1 and
the catalytic domain of murine DNMT3a complexed with the C-
terminal domain of DNMT3L (3a/3L) (Fig. 3). Hemimethylated
duplexes mds-C, mds-Z and mds-F are used for DNMT1 due to its
higher affinity for hemimethylated DNA [48] (Fig. 3A and 3B).
Hemimethylated duplexes are incubated with increasing concen-
trations of DNMT1 in the presence of 300 mM of AdoMet and
loaded on a native TBE gel (Fig. 3A). The complexes are detected
in the wells of the gel and, at lower concentrations of protein
migrate as smears in the gel. Qualitatively DNMT1 binds to mds-
Z duplex with higher affinity (about twice) than to mds-F and to
mds-C. To determine if this binding is covalent, SDS-PAGE gels
are realized in various conditions. No irreversible covalent
complex is detected when DNMT1 is incubated 16 h at 16uCo r
30uC, with mds-C (Fig. 3B, lanes 3, 4) and mds-Z (Fig. 3B, lanes 7,
8). The same results are obtained after 4 h at 37uC (data not
shown). In contrast, a covalent complex is detected on mds-F with
a mobility of approximately 266 kDa in accordance with the
molecular weight of tagged DNMT1 (240 kDa) and the duplex
(26 kDa) (Fig. 3B, lanes 11, 12). When the reaction is performed at
16uC we detect only a weak irreversible complex (Fig. 3B, lane 11).
Native and denaturing gels are also realized to analyze the
interaction between the three duplexes (ds) and of the catalytic
DNMT3a/3L (3a/3L) complex (Fig. 3C and 3D). In the native gel
the incubation conditions (1 h at 37uC) are chosen to avoid total
methylation of the ds-C duplexes. Complexes are detected in the
wells with all three duplexes (Fig. 3C). DNMT3a/3L binds slightly
better to the ds-Z duplex compared to the others. However, no
covalent complexes are observed in denaturing conditions after
16 h at 30uC (Fig. 3D, lanes 3, 6, 9), or 2 h at 37uC, or 16 h at
16uC (data not shown).
Methyl group transfer does not occur on zebularine
Another important issue is whether zebularine is methylated or
not by the enzymes. To address this question, ds-Z or ds-C
duplexes are incubated with or without M.SssI in the presence of
1 mM AdoMet 4 h at 37uC. Duplexes are then digested by
nuclease P1, phosphodiesterase and alkaline phosphatase [49].
LC/MS-MS analysis in MRM mode is then used to detect the
different nucleosides of the mixture (Fig. 4). We detected no C5-
methylzebularine (Fig. 4D). Noteworthy, the technique is very
sensitive (10 fmol). In addition, we observe that the enzyme does
not methylate the other CpG sites present in the duplex when
zebularine is present at one CpG. These results have been
confirmed by a tritium-labeled AdoMet incorporation assay (data
not shown).
Interestingly, AdoMet increases DNA enzyme binding and thus
complex formation with ds-C, ds-Z and ds-F (Fig. S3). This
suggests that the binding of the cofactor is important for complex
formation, even if in the case of ds-Z no methylation occurs on the
modified base.
Increased stability of the ternary complex on DNA
containing zebularine
Next the dissociation of M.SssI complexed with ds-C, ds-Z and
ds-F in the presence of AdoMet was studied by heat denaturing
experiments. Such a method was chosen, because preliminary
competition experiments with a 100-fold excess of unlabelled
duplexes did not show any dissociation even after 4 hours (data
not shown). In a first part of our study, we determined the
temperature (among 20uC, 55uC, 75uC and 90uC) at which
complex dissociation is observed without denaturing the duplex-
es. 55uC was chosen since dissociation is observed starting from
5 min of heating without dissociation of the duplex (Fig. 5A).
Complexes are preformed by incubating duplexes with or without
Figure 2. DNA binding and cross-linking of M.SssI by gel shift and SDS-PAGE analysis. 59 [c
32P]-labeled duplexes on the stranded
containing the modified base (ds-Z, ds-F and the control ds-C) or on the complementary strand (ds-F
#) were incubated with 0.2 mL (46 nM), 0.5 mL
(115 nM) or without M.SssI as mentioned on the top of the gel for 16 h at 16uC and loaded onto a 4% non-denaturing TBE 1X gel (A) or onto a 10%
SDS PAGE (B). Schematic representation of the labeled single-stranded DNA (––*) or ds (=*) are indicated on the right of the gel and the circle
represents the enzyme bound to labeled single-stranded or double-stranded DNA.
doi:10.1371/journal.pone.0012388.g002
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are then subjected to heating at 55uC during various times from
30 s to overnight, before loading onto a native TBE gel (Fig. 5A).
The ternary complex ds-Z/M.SssI/AdoMet is much more stable
than the one formed with ds-C. The dissociation times (t1/2)a r e
calculated from the mean dissociation curves of three indepen-
dent experiments represented in Fig. 5B and we obtained 2367s
for ds-C and 2265 min for ds-Z, and higher than 2 h with a
plateau at 30–40% of formed complex in the case of ds-F (Fig.
S4).
Figure3. NativeTBEandSDS-PAGE analysisofthebinding andcross-linking between DNMT1 (A andB),DNMT3a/L (CandD) toDNA.
M. SssI was used as control. 59 [c
32P]-labeled duplexes ds-C, ds-Z, ds-F (for MSss.I andDNMT3a/3L) or mds-C, mds-Z, mds-F (for DNMT1) (0.05 pmol) were
incubated with the specified methyltransferase. DNMT1 and DNMT3a/3L complex were incubated in buffer A supplemented by 300 mM of AdoMet;
M.SssI was incubated in the buffer supplied by NEB supplemented with 300 mM of AdoMet and 100 mg/mL of bovine serum albumin (BSA). (A) DNMT1
was used in excess of once (1X), twice (2X) or 5 times (5X) compared to the duplexes. Incubations were carried out for 4 h at 37uC. Samples were loaded
ona 4%nativeTBEgel. (B) mds-X wereincubated withDNMT1at28 nMfinal concentrationfor16 h at16uC(lanes3,7 and11)or 16 h at30uC(lanes4,8
and 12). As control ds-C, ds-Z and ds-F (lanes 2, 6 and 10, respectively) were incubated qith 0.5 mL of M.SssI (ca. 0.1 mg/mL) 16 h at 16uC. Samples were
loaded on a 10% SDS-PAGE gel. (C) DNMT3a/3L complex was used in excess of 10 (10X) to 500 (500X) compared to the duplexes. Incubations were
carried out for 1 h at 37uC. Samples were loaded on a 4% native TBE gel. (D) ds-X were incubated with DNMT3a/3L complex at 0.75 mM (final
concentration) or 0.5 mL of M.SssI (ca. 0.1 mg/mL). Incubations were carried out for 16 h at 30uC (for DNMT3a/3L) or 16uC (for M.SssI). The reaction
mixture was loaded onto a 10% denaturing SDS-PAGE. Schematic representation of the labeled single-stranded DNA (––*) or ds (=*) are indicated on
the right of the gels and the circle represents the enzyme bound to labeled single-stranded or double-stranded DNA.
doi:10.1371/journal.pone.0012388.g003
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Zebularine has been described as a potent inhibitor of DNA
methyltransferases forming a permanent covalent complex with
the enzymes [26,27,28]. Several studies have been carried out to
clarify the mechanism of methylation inhibition by this nucleoside
analog. It has been long debated why the covalent complex
between DNA methyltransferases and zebularine containing DNA
was permanent. Taylor et al. reported the formation of a covalent
link between a short DNA duplex containing deoxyzebularine and
M.MspI [27], showing however that these complexes are not as
stable as those observed with a DNA containing 5-F-CdR. The
authors extended their findings to M.HhaI [26] using the same
technique of denaturing by SDS prior to loading onto a non-
denaturing gel and observed that AdoMet and its analogs increase
complex formation. Finally, in 2002, Zhou et al. described the
interaction between the M.HhaI and a short duplex containing
zebularine [28] by X-ray crystallography observing the formation
of a covalent bond between the enzyme and zebularine. However,
according to the authors, it remains unexplained why the covalent
bond formed during the reaction with the enzyme and zebularine
might be permanent, i.e. why the b-elimination to reverse adduct
formation should not take place. A study using an electronic
structure-based algorithm predicted the inhibition by noncytosine
nucleotide targets [5]. Most recently, Darii et al. [46] showed that
M.SssI formed SDS-resistant complex with DNA containing
zebularine in presence of either AdoMet or AdoHcy by denaturing
Laemmli polyacrylamide gel analysis. However samples were not
heated before loading. Finally, van Bemmel et al. [44] analyzed the
difference between 5-aza-CdR and zebularine. They report that
oligonucleotides containing zebularine are competitive inhibitors
of both prokaryotic (M.HhaI) and mammalian DNMT (DNMT1).
Figure 4. LC-ESI-MS/MS extracted ion chromatograms of 29-deoxycytidine (dC, red line), 5-methyl-29-deoxycytidine (5mdC, blue
line) and zebularine (Z, green line). Chromatograms A and B show respectively nucleosides composition in ds-C before and after methylation by
M.SssI. Chromatograms C and D show respectively nucleosides composition in ds-Z before and after methylation by M.SssI.
doi:10.1371/journal.pone.0012388.g004
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is irreversible with the oligonucleotide containing 5-azacytosine
and reversible but stable for the one containing zebularine.
In this work, we studied the mechanisms of inhibition of
zebularine compared to 5-F-CdR on prokaryotic M.SssI and
mammalian DNMT 1 and DNMT3a/3L. We confirm that the
ternary complex between DNA containing zebularine, AdoMet
and the enzymes is reversible. In addition we clearly show that:
(i) the methyltransferases have a higher affinity for the
zebularine-containing DNA than unmodified DNA or the 5-F-
CdR-containing one. We measured the DNA binding of M.SssI
for the three duplexes (Fig. 2A and S1) and we found that,
although zebularine does not form a covalent complex with the
DNMTs tested, it increases the binding affinity of the enzyme for
the DNA by 2-folds.
Moreover in agreement with previous finding, AdoMet
increases the affinity (Fig. S3B). Similarly, DNMT1 and
DNMT3a/3L bind zebularine modified DNA with a higher
affinity than unmodified and 5-F-CdR duplexes (Fig. 3A and 3C).
However, in the case of hDNMT1 and murine catalytic
DNMT3a/3L, the DNA/enzymes complexes are detected in the
wells of the gel so it is difficult to do a quantitative analysis. We
assume that this is because we use for our studies 40mer duplexes
allowing the binding of several enzymes and thus the formation of
high molecular weight complexes that do not enter into the gel.
Yokochi et al. [50] have already performed gel shift analysis with
hDNMT1 and mDNMT3a on 21 pb long duplexes, revealing
multiple protein-DNA complexes, with 1, 2, 3 or 4 proteins bound
to the duplex. The higher DNA binding of the methyltransferases
for ds-Z can be explained by a reduction in the barrier to base
flipping since the lack of the amino group on zebularine implies
that the ZNG base pair is held by only 2 H bonds instead of 3
present in the unmodified CNG base pair. Moreover, the lack of 4-
amino group causes a profound increase in the electrophilic
character of the base compared with cytidine that facilitates the
nucleophilic attack taking place at C6 and formation of the
covalent intermediate [29,32].
(ii) We have shown that both prokaryotic and mammalian
DNMTs bind to the three duplexes by non denaturing gel analysis.
However we demonstrate by denaturing gel analysis that the
binding between zebularine containing DNA and the enzymes is
reversible and heat labile. This finding implies that the covalent
intermediate formed during the catalytic process between the
catalytic cysteine and the C6 of the base is not permanent. Van
Bemmel et al. showed that the complexes formed by DNMT1 and
M.HhaI with DNA containing zebularine are stable in the
presence of SDS at room temperature. However, theses complexes
completely dissociated at 75uC for M.HhaI. For DNMT1 only a
very small population of complex was still detectable at 95uC. The
authors suggest that zebularine is trapped by a covalent bond
formation with an unidentified electrophile in the catalytic pocket
of the enzyme. In our experimental conditions, we did not observe
such complexes. As control, we used 5-F-CdR-containing duplex
that clearly forms an irreversible DNA-enzyme complex with
M.SssI and DNMT1 detectable even after heating at 90uC (Fig. 2B
and 3B). No such covalent complex is observed with the murine
catalytic DNMT3a/3L complex, which can be explained by the
difference in the activity between the enzymes. Indeed, M.SssI and
DNMT1 are more active than DNMT3a/3L [47,51]. Reither
et al. have observed a covalent complex between DNA containing
5-fluorodeoxycytidine and the murine catalytic domain of
DNMT3a [52]; however, the complex was very weak.
(iii) No methylation of zebularine is observed by LC-MS/MS
analysis on digested ds-Z after incubation with M.SssI (Fig. 4).
This result is in agreement with the molecular orbital calculations
made by Zhou et al. [28], indicating that zebularine did not seem
to be methylated. This explains also the observation of van
Bemmel et al. [44] that the stability of M.Hha I complexed to
zebularine-containing DNA was independent of the use of
AdoMet or AdoHcy. In brief, our hypothesis is that the absence
of 4-amino group in zebularine does not allow the activation of the
cytosine C5 position after covalent intermediate formation and
thus transfer of the methyl group.
(iv) The dissociation rate of ds-Z complexed to M.SssI is
decreased of 57-folds compared to ds-C (Fig. 5B). It has been
described that the DNA/DNMT complex dissociates rapidly in
solution only after methylation of position 5 probably because of
steric clash [45,53–55]. Therefore the lack of methylation could
explain the stabilization of zebularine-containing DNA binding
complex as compared to the cytosine containing duplex ds-C. In
addition, in our experimental conditions, when zebularine is
present on the duplex, no methylation is observed even at the
other CpG sites present on the duplex.
Thus, even if it is reversible, the lack of zebularine methylation
seems to prevent the DNA/enzyme complex dissociation, and the
zebularine-containing DNA/M.SssI/AdoMet ternary complex is
much more stable than the one with unmodified DNA, indicating
that the covalent intermediate is stabilized. In line with previous
work [44], the fact that there is no permanent covalent bond with
DNMTs may explain why higher concentrations of zebularine are
needed to obtain similar levels of demethylation in cells in
comparison with 5-aza-CdR [31] and why its cytotoxicity is lower.
Materials and Methods
General reagents
Oligodeoxynucleotides were purchased from Eurogentec and
enzymes from New England Biolabs (NEB) or Roche Biochem-
icals, at the exception of DNMT1 (BPS Bioscience, CA) and
catalytic murine DNMT3a and 3L, which were purified as
described in [56]. [c
32P]ATP (3000 Ci/mmol) was purchased
from Perkin Elmer and Micro Bio-SpinH 6 columns from Biorad.
Nomenclature
ss stands for the single-stranded oligonucleotide containing
either deoxycytidine (ss-C), zebularine (ss-Z) or 5-fluorodeoxycy-
tidine (ss-F). When hybridized to the complementary strand, we
obtain duplexes ds-C, ds-Z and ds-F. mds means that the duplex is
hemimethylated, i.e. methylated on the complementary strand not
containing the modification.
Labeling and duplex formation
The indicated single-strand of the duplex was radiolabeled at its
59 by T4 polynucleotide kinase and [c
32P]ATP according to the
manufacture instructions. Then it was hybridized in 20 mM Tris
pH 7.5, 10 mM LiCl with 1.4 excess of unlabeled complementary
strand, heated at 90uC for 5 min and slowly cooled down to RT.
Figure 5. Dissociation analysis of the intermediate covalent complex. (A) ds-C or ds-Z were methylated by M.SssI during 16 h at 16uC before
being incubated at 55uC during 0 sec, 30 sec, 1 min, 5 min, 15 min, 1 h, 2 h, 4 h and overnight. Lanes ds-C and ds-Z are controls and correspond to
the duplexes loaded in the absence of the enzyme. The samples were run on a 10% non-denaturing gel. (B) Mean dissociation curves of 3
independent experiments for M.SssI/ds-C (red circles) and M.SssI/ds-Z (blue squares) complexes are reported with the standard error.
doi:10.1371/journal.pone.0012388.g005
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59 [c
32P] labeled duplexes ds-X (for MSss.I and DNMT3a/3L)
or mds-X (for DNMT1) (0.05 pmol) were incubated with specified
DNMTs at the concentration indicated in the figure legend:
M.SssI in the buffer supplied by NEB; DNMT1 (0.05 mg/mL)
and DNMT3a/3L complex in buffer A (20 mM HEPES pH 7.2,
1 mM EDTA, 50 mM KCl, 50 mg/mL BSA) supplemented with
300 mM of AdoMet. Incubations were carried out for 16 h at 16uC
(for M.SssI) or as described in the figure legend. The reaction
mixture was loaded onto a pre-run 4% non-denaturing polyacryl-
amide gel in TBE buffer or onto a 10% denaturing SDS-PAGE
after boiling in Laemmli buffer. The gels were vacuum-dried and
protein-DNA complexes were visualized on a Typhoon (GE
Healthcare). All experiments were performed in replicate
independently.
Methylation status of zebularine
ds-Z (1 nmol) were incubated with M.SssI and then digested by
nuclease P1 (2 h at 45uC in 0.01 M AcONH2 buffer), snake
venom phosphodiesterase (2 h at 37uC in 0.1 M NH4HCO3
buffer) and antarctic alkaline phosphatase (1 h at 37uC) according
to the procedure described by Song et al. [49]. Products were then
analyzed by LC-MS/MS in MRM mode with the monitor of 4
transition pairs. dC, 5mdC and Z were detected respectively by
monitoring m/z 228.2/112.2, m/z 242.2/126.2 and m/z 229.2/
97.2. 5-methylzebularine was searched by monitoring m/z 243.2/
111.2 but was not detected.
Alternatively, the methylation status was also tested in an in vitro
radioactive methylation assay. DNA methylation activity of the
complex is measured by the incorporation of tritiated methyl
groups from labeled S-[methyl-
3H] AdoMet (specific activity
370 GBq/mmol, Perkin Elmer) into the DNA substrates. The
methylation reactions were carried out in the NEB methylation
buffer, using 0.1 mM DNA, 0.5 mM of labeled AdoMet, 0.5 mMo f
non-labeled AdoMet and 0.5 mM of M.SssI. The methylation
reactions were started by the addition of substrate DNA and
allowed to proceed for 1 hour at 37uC. Reaction were stopped on
a Micro Bio-Spin 30 column (BioRad) and measured in 4 mL of
scintillate liquid.
All experiments were performed in duplicate or triplicate
independently.
Ternary complex dissociation studies
59 [c
32P] labeled duplexes ds-X (for MSss.I) (0.05 pmol) were
incubated with or without M.SssI (1 mL of M.SssI (ca. 0.1 mg/
mL)) in the buffer supplied by NEB supplemented with 1 mMo f
AdoMet and 100 mg/mL of bovine serum albumin (BSA).
Incubations were carried out for 16 h at 16uC and samples were
then heated at 55uC during various times from 30 s to overnight.
The reaction mixture was loaded onto a pre-run 4% non-
denaturing polyacrylamide gel in TBE buffer and protein-DNA
complexes were visualized on a Typhoon (GE Healthcare). All
experiments were performed in triplicate independently.
Supporting Information
Figure S1 Binding analysis of the three duplexes with M.SssI on
native TBE gels. 59 [c32P]-labeled duplexes on the stranded
containing the modified base (ds-Z, ds-F and the control ds-C)
(0.05 pmol) were incubated with or without various amount of
M.SssI in the buffer supplied by NEB supplemented with 300 mM
of AdoMet and 100 mg/mL of bovine serum albumin (BSA) for
16 h at 16uC. Concentrations of enzyme used were 23 nM,
69 nM, 92 nM, 115 nM, 161 nM and 230 nM for ds-C and ds-F
and 11 nM, 23 nM, 34.5 nM, 46 nM, 57.5 nM, 69 nM, 92 nM
and 115 nM for ds-Z. Samples were loaded on a 4% non-
denaturing TBE gel. (A) Representative gel. Lanes ds-C, ds-Z and
ds-F are controls and correspond to the duplexes loaded in the
absence of the enzyme. Schematic representation of the labeled
double-stranded DNA (=*) is indicated on the right of the gel and
the circle represents the enzyme bound to labeled double-stranded
DNA. Bands of slower mobility correspond probably to multiple
complexes. (B) Quantitative analysis of the above gel. Experiments
have been replicated twice for ds-C and ds-F and four times for ds-
Z to determine the mean of C50, concentration at which 50% of
complex is formed, given in text.
Found at: doi:10.1371/journal.pone.0012388.s001 (2.86 MB TIF)
Figure S2 Covalent complex formation with 5-fluorocytidine (5-
F-CdR). (A) Denaturing gel analysis of the cross-linking between
M.SssI and the duplex containing 5-F-CdR 59 [c32P]-labeled on
the stranded containing the modified base (dsF) or on the on the
complementary strand (ds-F#). ds-F or ds-F# are incubated with
M.SssI at 16uC for 16 h and then treated with proteinase K (PK)
1 h at 37uC when specified on the top of the gel before loading
onto a 8% polyacrylamide denaturing gel (7M urea and TBE
1X). Schematic representation of the labeled single-stranded DNA
(––*) is indicated on the right of the gel and the circle represents
the enzyme covalently bound to labeled single-stranded DNA. A
band with retarded mobility appears only when the strand
containing 5-F-CdR is labeled. Moreover when reaction mixtures
are treated with proteinase K before loading, the retarded band
disappears and products of enzyme degradation appear. These
data show that M.SssI was covalently bound only on the modified
strand. (B) Mechanism of covalent complex formation between
5-F-CdR and DNMT. Following covalent bond formation at
position C6 and methyl transfer, the analogue remains bound to
the active-site Cys, since b-elimination cannot be achieve.
Found at: doi:10.1371/journal.pone.0012388.s002 (1.92 MB TIF)
Figure S3 Effect of AdoMet on the binding and cross-linking of
M.SssI. 59 [c32P]-labeled ds-C (lane 1), ds-Z (lane 4) or ds-F (lane
7) were incubated with M.SssI, without (lanes 2, 5 and 8) or with
AdoMet (lanes 3, 6 or 9) as mentioned on the top of the gel for
16 h at 16uC and loaded onto a 10% SDS-PAGE (A) or 4% non-
denaturing TBE gel (B). The circle represents the enzyme bound
to labeled double-stranded DNA. Schematic representation of the
labeled single-stranded DNA (––*) or ds (=*) are indicated on the
right of the gel and the circle represents the enzyme covalently
bound to labeled single-stranded or double-stranded DNA.
Found at: doi:10.1371/journal.pone.0012388.s003 (1.13 MB TIF)
Figure S4 Dissociation analysis of the intermediate covalent
complex between M.SssI and the 5-F-CdR-containing duplex (ds-
F). (A) The duplex was incubated without M.SssI (lane ds-F) or
with M.SssI during 16 h at 16uC before being incubated at 55uC
during 0 sec, 15 min, 1 h, 4 h and overnight. The M.SssI/DNA
complexes were analyzed on a non-denaturing gel. (B) Mean
dissociation curves of 3 independent experiments for M.SssI/ds-F
complexes is reported. Errors bars represent standard deviation.
The graph is done with Prism software.
Found at: doi:10.1371/journal.pone.0012388.s004 (2.08 MB TIF)
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